Northland Securities Remains a Hold on Irhythm Technologies (IRTC)


In a report released today, Suraj Kalia from Northland Securities maintained a Hold rating on Irhythm Technologies (IRTC), with a price target of $75. The company’s shares opened today at $91.04.

According to TipRanks.com, Kalia is a 5-star analyst with an average return of 13.0% and a 59.3% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.

Currently, the analyst consensus on Irhythm Technologies is a Moderate Buy with an average price target of $101.14.

See today’s analyst top recommended stocks >>

Based on Irhythm Technologies’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.71 million. In comparison, last year the company had a GAAP net loss of $11.15 million.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts